Steven Miller

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction

Keith A. Hruska, Guangjie Guo, Magdalena Woźniak et al. · American Journal of Physiology-Renal Physiology · 2000 · 247 citations

Medicine, Nephrology, Pathobiology +16

EPIDEMIC MALATHION POISONING IN PAKISTAN MALARIA WORKERS

Edward L. Baker, Matthew M. Zack, James W. Miles et al. · The Lancet · 1978 · 154 citations

Pharmacy, Infectious Diseases, Toxicology +10